ASTELLAS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ASTELLAS
ASTELLAS has thirty-seven approved drugs.
There are thirty-one US patents protecting ASTELLAS drugs. There is one tentative approval on ASTELLAS drugs.
There are four hundred and sixty-three patent family members on ASTELLAS drugs in forty-three countries and eighty-one supplementary protection certificates in twenty countries.
Summary for ASTELLAS
| International Patents: | 463 |
| US Patents: | 31 |
| Tradenames: | 21 |
| Ingredients: | 16 |
| NDAs: | 37 |
| Patent Litigation for ASTELLAS: | See patent lawsuits for ASTELLAS |
Drugs and US Patents for ASTELLAS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | ARISTOCORT | triamcinolone | TABLET;ORAL | 011161-007 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Astellas | ASTAGRAF XL | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 204096-002 | Jul 19, 2013 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astellas | XOSPATA | gilteritinib fumarate | TABLET;ORAL | 211349-001 | Nov 28, 2018 | RX | Yes | Yes | 11,938,131 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-001 | Aug 4, 2020 | AB | RX | Yes | No | 11,839,689 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Astellas | CRESEMBA | isavuconazonium sulfate | POWDER;INTRAVENOUS | 207501-001 | Mar 6, 2015 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ASTELLAS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 7,655,637 | ⤷ Start Trial |
| Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-003 | Jun 27, 2006 | 6,265,536 | ⤷ Start Trial |
| Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-003 | Jun 27, 2006 | 5,376,634 | ⤷ Start Trial |
| Astellas | ADENOCARD | adenosine | INJECTABLE;INJECTION | 019937-002 | Oct 30, 1989 | 4,673,563 | ⤷ Start Trial |
| Astellas | ASTAGRAF XL | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 204096-002 | Jul 19, 2013 | 6,576,259 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ASTELLAS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-18 |
| ➤ Subscribe | Injection | 0.08 mg/mL, 5 mL vial | ➤ Subscribe | 2012-04-10 |
| ➤ Subscribe | Extended-release Capsules | 0.5 mg, 1 mg, and 5 mg | ➤ Subscribe | 2013-11-15 |
| ➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2014-06-16 |
| ➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-16 |
| ➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2009-04-08 |
| ➤ Subscribe | Capsules | 40 mg | ➤ Subscribe | 2016-08-31 |
International Patents for ASTELLAS Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20110041580 | ⤷ Start Trial |
| Slovenia | 2948455 | ⤷ Start Trial |
| Australia | 2007302320 | ⤷ Start Trial |
| Spain | 3058378 | ⤷ Start Trial |
| China | 110193009 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ASTELLAS Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0788511 | SPC/GB08/036 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425 |
| 0801067 | SPC/GB04/029 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816 |
| 1893196 | 491 | Finland | ⤷ Start Trial | |
| 1280795 | CR 2016 00002 | Denmark | ⤷ Start Trial | PRODUCT NAME: ISAVUCONAZOLE AS ISAVUCONAZONIUM SULFATE OR AS AN ISAVUCONAZONIUM SALT WITH ANY OTHER PHARMACEUTICALLY ACCEPTABLE ANION, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE; REG. NO/DATE: EU/1/15/1036 20151019 |
| 1280795 | 2015/073 | Ireland | ⤷ Start Trial | PRODUCT NAME: ISAVUCONAZOLE AS ISAVUCONAZONIUM SULFATE OR AS ISAVUCONAZONIUM SALT WITH ANY OTHER PHARMACEUTICALLY ACCEPTABLE ANION, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE; REGISTRATION NO/DATE: EU/1/15/1036 20151015 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
